Biogen Financial Statements From 2010 to 2024

BIIB Stock  USD 277.00  0.46  0.17%   
Biogen financial statements provide useful quarterly and yearly information to potential Biogen Inc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Biogen financial statements helps investors assess Biogen's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Biogen's valuation are summarized below:
Gross Profit
7.9 B
Profit Margin
0.1207
Market Capitalization
33.7 B
Enterprise Value Revenue
3.5683
Revenue
9.7 B
We have found one hundred twenty available fundamental signals for Biogen Inc, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Biogen Inc prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. As of June 16, 2024, Market Cap is expected to decline to about 4.2 B. In addition to that, Enterprise Value is expected to decline to about 4.2 B

Biogen Total Revenue

10.33 Billion

Check Biogen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biogen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 256.8 M, Interest Expense of 259.2 M or Selling General Administrative of 2.6 B, as well as many indicators such as Price To Sales Ratio of 3.62, Dividend Yield of 0.0022 or PTB Ratio of 2.4. Biogen financial statements analysis is a perfect complement when working with Biogen Valuation or Volatility modules.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

Biogen Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets28.2 B26.8 B19.5 B
Slightly volatile
Short and Long Term Debt Total7.7 B7.3 B4.8 B
Slightly volatile
Other Current Liabilities969.8 M838.4 MB
Slightly volatile
Total Current Liabilities3.6 B3.4 B2.8 B
Slightly volatile
Total Stockholder Equity15.5 B14.8 B10.6 B
Slightly volatile
Property Plant And Equipment Net3.9 B3.7 B2.7 B
Slightly volatile
Cash723.1 MB1.4 B
Slightly volatile
Non Current Assets Total21 B20 B13.3 B
Slightly volatile
Cash And Short Term Investments1.5 BB2.7 B
Slightly volatile
Net Receivables2.2 B2.1 B1.4 B
Slightly volatile
Common Stock Shares Outstanding283 M145.6 M222.8 M
Slightly volatile
Liabilities And Stockholders Equity28.2 B26.8 B19.5 B
Slightly volatile
Non Current Liabilities TotalB8.6 B6.1 B
Slightly volatile
Other Current Assets1.2 B1.2 B1.1 B
Slightly volatile
Total Liabilities12.6 B12 B8.9 B
Slightly volatile
Property Plant And Equipment Gross6.4 B6.1 B3.1 B
Slightly volatile
Total Current Assets7.2 B6.9 B6.1 B
Slightly volatile
Intangible Assets8.8 B8.4 B3.6 B
Slightly volatile
Accounts Payable423.5 M403.3 M336.5 M
Slightly volatile
Common Stock Total Equity85.5 K90 K121.2 K
Slightly volatile
Common Stock85.5 K90 K121.2 K
Slightly volatile
Short Term Debt254.1 M150 M336.9 M
Pretty Stable
Inventory2.7 B2.5 B1.1 B
Slightly volatile
Other Liabilities969.6 M1.5 B1.4 B
Slightly volatile
Other AssetsB1.9 B1.4 B
Slightly volatile
Long Term Debt7.1 B6.8 B4.4 B
Slightly volatile
Property Plant Equipment2.1 B3.8 B2.5 B
Slightly volatile
Good Will3.2 B6.2 B3.7 B
Slightly volatile
Net Tangible Assets4.1 B6.7 BB
Slightly volatile
Retained Earnings Total Equity11.5 B18.9 B11.7 B
Slightly volatile
Long Term Debt Total4.3 B7.2 B4.3 B
Slightly volatile
Capital Surpluse62.7 M66 M1.5 B
Slightly volatile
Deferred Long Term Liabilities631.7 M384.9 M590.4 M
Slightly volatile
Non Current Liabilities Other1.1 B781.1 MB
Slightly volatile
Short and Long Term Debt163.9 M172.5 M367 M
Slightly volatile
Net Invested Capital13.8 B21.7 B17.7 B
Slightly volatile
Net Working Capital4.6 B3.4 B4.3 B
Pretty Stable
Capital Stock80 K90 K98 K
Slightly volatile
Deferred Long Term Asset ChargesB3.7 B2.6 B
Slightly volatile
Capital Lease Obligations300.5 M400 M392.9 M
Slightly volatile

Biogen Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization256.8 M494.8 M416.3 M
Slightly volatile
Selling General Administrative2.6 B2.5 B1.9 B
Slightly volatile
Total Revenue10.3 B9.8 B9.6 B
Slightly volatile
Gross Profit3.9 B7.3 B7.9 B
Slightly volatile
Other Operating Expenses8.4 BB6.1 B
Slightly volatile
Cost Of Revenue2.7 B2.5 B1.5 B
Slightly volatile
Total Operating Expenses5.7 B5.5 B4.6 B
Slightly volatile
Income Tax Expense128.5 M135.3 M792.6 M
Very volatile
Research Development1.4 B2.5 BB
Slightly volatile
Net Income Applicable To Common SharesB3.5 B2.8 B
Slightly volatile
Net Income From Continuing Ops1.1 B1.2 B2.7 B
Pretty Stable
Non Recurring99.1 M118 M119.8 M
Pretty Stable
Selling And Marketing Expenses93.1 M71.4 M81.1 M
Slightly volatile
Tax Provision128.5 M135.3 MB
Slightly volatile
Interest Income290.3 M276.5 M114.2 M
Slightly volatile
Reconciled Depreciation523.9 M494.8 M845 M
Slightly volatile

Biogen Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow3.6 B3.4 B1.6 B
Slightly volatile
Capital Expenditures429.3 M311.4 M735.5 M
Pretty Stable
Net Income1.3 B1.2 B2.6 B
Pretty Stable
End Period Cash Flow800.3 MB1.4 B
Slightly volatile
Stock Based Compensation195.9 M264.2 M164 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.623.80710.9432
Slightly volatile
Dividend Yield0.00220.00230.0024
Slightly volatile
PTB Ratio2.42.53015.6297
Slightly volatile
Days Sales Outstanding74.8677.931253.8262
Slightly volatile
Book Value Per Share10710258.0095
Slightly volatile
Invested Capital0.520.49580.406
Slightly volatile
Stock Based Compensation To Revenue0.02570.02690.0173
Slightly volatile
PB Ratio2.42.53015.6297
Slightly volatile
EV To Sales4.224.446311.0206
Slightly volatile
Inventory Turnover1.861.00241.5242
Slightly volatile
Days Of Inventory On Hand277364270
Slightly volatile
Payables Turnover4.366.28174.8192
Pretty Stable
Sales General And Administrative To Revenue0.160.2520.199
Pretty Stable
Research And Ddevelopement To Revenue0.390.25030.25
Pretty Stable
Cash Per Share5.267.255714.0643
Slightly volatile
POCF Ratio37.7924.201128.1862
Slightly volatile
Payout Ratio0.740.460.4585
Very volatile
Days Payables Outstanding55.258.105584.6128
Pretty Stable
Intangibles To Total Assets0.570.54320.3558
Slightly volatile
Current Ratio1.91.99732.5993
Slightly volatile
Tangible Book Value Per Share1.431.50115.6333
Very volatile
Receivables Turnover4.854.68367.0636
Slightly volatile
Graham Number143136128
Slightly volatile
Shareholders Equity Per Share10710258.0095
Slightly volatile
Debt To Equity0.520.49580.406
Slightly volatile
Revenue Per Share71.3767.972452.0162
Slightly volatile
Interest Debt Per Share55.0452.419528.4773
Slightly volatile
Debt To Assets0.290.27340.2119
Slightly volatile
Short Term Coverage Ratios9.810.3147360
Slightly volatile
Operating Cycle464442291
Slightly volatile
Price Book Value Ratio2.42.53015.6297
Slightly volatile
Days Of Payables Outstanding55.258.105584.6128
Pretty Stable
Dividend Payout Ratio0.740.460.4585
Very volatile
Price To Operating Cash Flows Ratio37.7924.201128.1862
Slightly volatile
Ebt Per Ebit1.461.391.0378
Slightly volatile
Company Equity Multiplier1.151.81391.721
Slightly volatile
Long Term Debt To Capitalization0.340.32690.2566
Slightly volatile
Total Debt To Capitalization0.350.33150.2674
Slightly volatile
Debt Equity Ratio0.520.49580.406
Slightly volatile
Quick Ratio0.870.91721.9157
Slightly volatile
Net Income Per E B T0.920.89540.7931
Pretty Stable
Cash Ratio0.290.30570.9459
Slightly volatile
Cash Conversion Cycle403384207
Slightly volatile
Days Of Inventory Outstanding277364270
Slightly volatile
Days Of Sales Outstanding74.8677.931253.8262
Slightly volatile
Cash Flow Coverage Ratios0.20.21081.2215
Slightly volatile
Price To Book Ratio2.42.53015.6297
Slightly volatile
Fixed Asset Turnover2.052.63713.4256
Pretty Stable
Price Cash Flow Ratio37.7924.201128.1862
Slightly volatile
Debt Ratio0.290.27340.2119
Slightly volatile
Cash Flow To Debt Ratio0.20.21081.2215
Slightly volatile
Price Sales Ratio3.623.80710.9432
Slightly volatile
Asset Turnover0.340.36640.4866
Pretty Stable
Gross Profit Margin0.510.74240.8213
Slightly volatile
Price Fair Value2.42.53015.6297
Slightly volatile

Biogen Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap4.2 B5.9 BB
Pretty Stable
Enterprise Value4.2 B6.4 B6.5 B
Pretty Stable

Biogen Fundamental Market Drivers

Forward Price Earnings13.0039
Cash And Short Term InvestmentsB

Biogen Upcoming Events

13th of February 2024
Upcoming Quarterly Report
View
23rd of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Biogen Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Biogen income statement, its balance sheet, and the statement of cash flows. Biogen investors use historical funamental indicators, such as Biogen's revenue or net income, to determine how well the company is positioned to perform in the future. Although Biogen investors may use each financial statement separately, they are all related. The changes in Biogen's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Biogen's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Biogen Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Biogen. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred RevenueB2.1 B
Total Revenue9.8 B10.3 B
Cost Of Revenue2.5 B2.7 B
Stock Based Compensation To Revenue 0.03  0.03 
Sales General And Administrative To Revenue 0.25  0.16 
Research And Ddevelopement To Revenue 0.25  0.39 
Capex To Revenue(0.03)(0.03)
Revenue Per Share 67.97  71.37 
Ebit Per Revenue 0.13  0.14 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Information and Resources on Investing in Biogen Stock

When determining whether Biogen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biogen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biogen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biogen Inc Stock:
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.011
Earnings Share
7.99
Revenue Per Share
66.688
Quarterly Revenue Growth
(0.07)
Return On Assets
0.0486
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.